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Patients with Primary Brain Tumors”We read with great interest the article by Lai et al., “Development
of a Symptom Index for Patients with Primary Brain Tumors” [1].
Although we agree on the importance of symptom assessment in
patients with primary brain tumors, we would like to clarify
several points in the article related to the MD Anderson Symptom
Inventory for Brain Tumor (MDASI-BT):1. We agree that incorporation of input from both patients and
clinicians is critical for instrument development. The author
suggests in the discussion that the MDASI-BT did not incor-
porate patient or clinician input and that it was not developed
speciﬁcally for patients with advanced brain tumors.
a. The MDASI-BT design and validation process did incorporate
clinician, patient, and caregiver input about the symptoms
included in the instrument, including review of suggested
symptoms and allowance for suggestion of important items
not initially included [2]. In addition, calculation of a content
validity index was undertaken [3].
b. An additional critique is the lack of validation of existing
instruments in patients with advanced brain tumors. We
might mention that the MDASI-BT validation work
included patients with all grades of primary tumors and
both patients who were on treatment and patients who
had experienced recurrence [2]. Since the initial validation,
additional work has shown the MDASI-BT’s sensitivity to
tumor progression on magnetic resonance imaging [4], as
well as its ability to predict both overall survival and
progression-free survival and sensitivity to between-arm
treatment differences, as evidenced in two of the largest
randomized clinical trials among patients with brain
tumor completed to date [5,6].2. One of the article’s arguments for the need for a symptom
index is that there are differences between the European
Organization for Research and Treatment C30-BN20 and the
MDASI-BT. These differences, however, are not unexpected
because the former is a quality-of-life measure and the latter
is a measure of symptom burden.3. Lai et al. commented that the 0 to 10 rating scale does not
distribute equally on a measurement continuum and
should not be used to measure change over time. However,
this claim was based on comparing a single pain item rated
on a 0 to 10 scale against a six-item short form and an item
bank with 43 items. There is no question that a single item
will perform poorly in this comparison as far as measure-
ment precision is concerned. Note, however, that this claim
goes against the National Institutes of Health Toolbox’s recom-
mended use of a 0 to 10 scale to assess pain intensity [7] and isial support: The authors have no other ﬁnancial relain contrast with the adoption of the 0 to 10 scale for rating
pain in the 10-item global Patient-Reported Outcomes Mea-
surement Information System assessment, in which pain is
the only item measured using the 0 to 10 scale [8].4. An additional critique centers on the recall time frame. The
authors claim that a 7-day time frame may better represent
the patient’s real experiences than the 24-hour time frame
used by the MDASI-BT. We agree that this is an important
question. We recently published our work in the brain tumor
population comparing 7-day and 24-hour reports, with this
initial study showing congruence between the two time
frames [9]. This same article showed desirable psychometric
properties for the MDASI-BT with a 7-day recall.5. Finally, most of the ﬁnal items included in the National
Comprehensive Cancer Network/Functional Assessment of
Cancer Therapy-Brain Symptom Index (NFBrSI-24) are
included in the MDASI-BT as well. Some items identiﬁed (such
as headaches and fear of having seizures) were considered in
the initial validation study of the MDASI-BT and were found to
be redundant with items that were eventually retained; other
items were consistently rated by patients as less severe and
proved to be less discriminatory, and therefore were removed
from the ﬁnal MDASI-BT. Several items in the NFBrSI do not
truly represent symptoms and their inclusion on a symptom
measure is a matter of debate.
In summary, we believe that the NFbrSI may be a useful tool
under appropriate circumstances. Even so, we appreciate the
opportunity to provide clariﬁcation regarding the development
and use of the MDASI-BT.
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